transrenal DNA

(redirected from tr-DNA)

transrenal DNA

(trans″rēn′ăl, tranz″) [ trans- + renal],

tr-DNA

Short sequences of nucleic acid base pairs, typically less than 180 base pairs in length, that are excreted and detected in the urine. They have been used as a means of diagnosing a variety of malignant and infectious diseases.
References in periodicals archive ?
Urine samples were also collected from 30 of these 100 patients for the quantification of Tr-DNA (mean, 7 samples/patient).
tCF-DNA and Tr-DNA were quantified by real-time PCR amplification of the HBB gene in an ABI Prism 7000 Sequence Detection System (Applied Biosystems).
Typical reference Tr-DNA concentrations ranged up to 140 GE/mL (90% CI, 120-180 GE/mL), with a median of 55 GE/mL (95% CI, 43-68 GE/mL).
An increase in Tr-DNA concentration was observed during the development of 2 AR episodes, and a rapid decrease was also observed after the start of antirejection treatment.
Significant increases in both plasma tCF-DNA and Tr-DNA concentrations were observed in patients with posttransplantation infections.
Both Tr-DNA and ddCF-DNA concentrations increased during AR.
Using a new proprietary method for isolation of Tr-DNA, Xenomics' scientists successfully detected sequences of a single copy Y chromosome-specific SRY gene in urine of women pregnant with male fetuses from the 6th week of pregnancy.
Since use of Tr-DNA for molecular diagnostics is a platform technology, success in one area based on significant improvements of Tr-DNA isolation and detection methodologies will accelerate test development in other fields including oncology, infectious diseases, and transplantation.
Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA.
These results were obtained when new proprietary methods of Tr-DNA isolation and analysis were applied for prenatal testing.
Taken together these two methods dramatically increased sensitivity of our Tr-DNA technology for prenatal and other applications.
Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk HPV and development of other tests based on Tr-DNA and Tr-miRNA.